Agendia Touts ASCO Guideline's Endorsement Of MammaPrint Breast Cancer Test
Results of the MINDACT trial, which show that Agendia BV's MammaPrint 70-gene lab test can identify about half of the early-stage breast cancer patients who do not need chemotherapy, has led the American Society of Clinical Oncology to specifically recommend the test in its guidelines.
You may also be interested in...
Myriad Genetics, Lumicell, and Agendia were among the companies with diagnostic technologies featured in the scientific presentations at the recent San Antonio Breast Cancer Symposium. New trials show that Myriad's EndoPredict can help identify patients who should not have preoperative chemotherapy. New Phase II data support Lumicell's LUM system for guiding excision of residual tumor and preventing cancer recurrence. Agendia's MammaPrint test proved cost-effective in the MINDACT trial.
By identifying the patients at low risk for recurrence, MammaPrint could spare more than 100,000 women with early-stage breast cancer worldwide from unnecessary chemotherapy, according to Agendia.
NWW: Studies Back Nevro Pain Treatment, FTC Blesses Resonetics Nitinol Deal, Genetic Test Identifies Best RDN Patients
This week, studies supported Nevro’s spinal cord stimulation therapy and a VRx system that helps reduce pain; the American Medical Association found inconsistent insurance coverage of digital therapeutics; and Geneticure announced a cheek-swab test to identify which patients are most likely to benefit from renal denervation.